NZ706862A - Agent for preventing or improving decline in brain function - Google Patents

Agent for preventing or improving decline in brain function

Info

Publication number
NZ706862A
NZ706862A NZ706862A NZ70686213A NZ706862A NZ 706862 A NZ706862 A NZ 706862A NZ 706862 A NZ706862 A NZ 706862A NZ 70686213 A NZ70686213 A NZ 70686213A NZ 706862 A NZ706862 A NZ 706862A
Authority
NZ
New Zealand
Prior art keywords
decreased
agent
preventing
salt
brain function
Prior art date
Application number
NZ706862A
Other languages
English (en)
Inventor
Kota Kumagai
Masahiko Morita
Takahiro Hara
Kohji Fukunaga
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of NZ706862A publication Critical patent/NZ706862A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ706862A 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function NZ706862A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012238541 2012-10-30
PCT/JP2013/080052 WO2014069666A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (1)

Publication Number Publication Date
NZ706862A true NZ706862A (en) 2019-03-29

Family

ID=50627558

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ706862A NZ706862A (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Country Status (8)

Country Link
US (1) US10369186B2 (enExample)
EP (1) EP2914257B1 (enExample)
JP (1) JP6170166B2 (enExample)
AU (1) AU2013339057B2 (enExample)
CA (1) CA2888791C (enExample)
ES (1) ES2728471T3 (enExample)
NZ (1) NZ706862A (enExample)
WO (1) WO2014069666A1 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110392A (en) * 1964-09-28 1968-04-18 Yamanouchi Pharma Co Ltd Composition containing glutathione and an amino acid or amino acids, and salts thereof
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
AU5939901A (en) * 2000-10-27 2002-05-06 Nitromed Inc Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2002333018B2 (en) * 2001-09-27 2006-08-31 The Mental Health Research Institute Of Victoria Modulation of physiological processes and agents useful for same
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP4137906B2 (ja) * 2005-03-30 2008-08-20 ピアス株式会社 セラミダーゼ阻害剤
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
US8597640B2 (en) 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
AU2008347177B2 (en) * 2008-01-04 2014-04-17 Société des Produits Nestlé S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
WO2009096505A1 (ja) * 2008-01-30 2009-08-06 Kyowa Hakko Bio Co., Ltd. 注意集中力向上剤
US9918951B2 (en) 2008-02-05 2018-03-20 Kyowa Hakko Bio Co., Ltd. Method for improving storage stability of glutathione
JP2010126462A (ja) * 2008-11-26 2010-06-10 Mitsubishi Gas Chemical Co Inc 脳機能改善用組成物および該組成物を含有する機能性食品

Also Published As

Publication number Publication date
JP2015535240A (ja) 2015-12-10
EP2914257A1 (en) 2015-09-09
ES2728471T3 (es) 2019-10-24
CA2888791A1 (en) 2014-05-08
US10369186B2 (en) 2019-08-06
JP6170166B2 (ja) 2017-07-26
AU2013339057A1 (en) 2015-04-30
EP2914257B1 (en) 2019-04-03
AU2013339057B2 (en) 2018-08-30
EP2914257A4 (en) 2016-07-27
US20150265670A1 (en) 2015-09-24
CA2888791C (en) 2021-07-27
WO2014069666A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
IN2015DN01198A (enExample)
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX379044B (es) Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal.
MA37975A1 (fr) Inhibiteurs de synthase de glucosylcéramide
CR20150174A (es) Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio
NZ707081A (en) Agent for preventing or improving decline in brain function
PH12015500900A1 (en) A stabilized pemetrexed formulation
BR112015023987A2 (pt) creme dental de duas fases
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
MX2014016121A (es) Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.
PH12016501005A1 (en) Anti-malodor oral care composition
MX2015005284A (es) Control de niveles de dioxido de carbono y ph en reactores de pequeños volumenes,.
IN2014KN02914A (enExample)
BR112014029264A2 (pt) microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo
JP2015535241A5 (enExample)
GB2521979A (en) A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient
IN2014KN02745A (enExample)
MX2013008277A (es) Composicion liquida y acousa de bromfenaco, que tiene efectividad conservadora.
WO2012068038A3 (en) Caffeic acid derivatives and their use in improving neuronal cell viability
WO2014031982A3 (en) Methods and compositions for treating pain
MY170840A (en) Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2015001524A3 (en) Stabilization of rose dedifferentiated cells
PH12013500497A1 (en) Composition for improving brain function and method for improving brain function
JP2015535240A5 (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2020 BY CPA GLOBAL

Effective date: 20190912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2021 BY CPA GLOBAL

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2022 BY CPA GLOBAL

Effective date: 20210916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2023 BY CPA GLOBAL

Effective date: 20220915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2024 BY CPA GLOBAL

Effective date: 20230914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250918